4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 94 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $222,469 | -94.3% | 17,476 | -91.9% | 0.00% | -100.0% |
| Q2 2023 | $3,895,459 | -10.6% | 215,576 | +9.9% | 0.00% | 0.0% |
| Q4 2022 | $4,357,624 | +5026.6% | 196,201 | +1759.9% | 0.00% | – |
| Q3 2022 | $85,000 | +13.3% | 10,549 | -1.0% | 0.00% | – |
| Q2 2022 | $75,000 | -54.0% | 10,653 | -0.9% | 0.00% | – |
| Q1 2022 | $163,000 | -32.4% | 10,745 | -2.1% | 0.00% | – |
| Q4 2021 | $241,000 | – | 10,980 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |